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Objective: To image and quantify the in vivo anti-inflammatory effects of everolimus-eluting stents (EES) versus bare metal stents (BMS) in 
protease-rich atheromata in rabbits.
Background: Local stent-based therapy is an intriguing strategy to treat inflammation associated with the progression and complications of 
atherosclerotic vascular disease. Intravascular catheter-based molecular imaging offers a clinically translatable strategy to understand the biological 
efficacy of drug-eluting stents on plaque inflammation in vivo.
Methods: New Zealand White rabbits (n=5) underwent aortoiliac balloon injury and 4 weeks of high cholesterol feeding. The aorta and iliac 
arteries underwent placement of non-overlapped coronary EES (XIENCE V®) and BMS (ML VISION®). Four weeks later, rabbits received an intravenous 
injection of a cathepsin protease-activatable NIRF imaging agent (Prosense750/VM110). A new 2D NIRF imaging catheter with automated pullback 
capabilities was utilized for in vivo intravascular NIRF imaging. Twenty-four hours following injection, angiography, intravascular ultrasound and 2D 
NIRF imaging of the aorta were performed. NIRF imaging was performed through blood without flushing. Resected aortoiliac vessels underwent ex 
vivo correlation using fluorescence reflectance imaging and confocal microscopic analysis.
Results: In vivo intravascular NIRF molecular imaging revealed that EES reduced plaque inflammatory protease activity (measured via target-
to-background ratios) by >50 percent compared to both adjacent BMS and unstented atheroma segments (ANOVA p<0.05). Findings were 
corroborated by ex vivo NIRF imaging and confocal microscopy. Immunohistochemical staining of RAM-11 antigen confirmed the presence of 
macrophages in inflamed areas.
Conclusions: Intravascular NIRF molecular imaging demonstrates that EES markedly suppresses plaque inflammation in vivo, in contradistinction 
to BMS. These data additionally provide a translatable molecular imaging methodology to understand the biological efficacy of DES therapies in 
clinical subjects.
